Cian Healthcare Limited, in its board meeting dated May 30, 2026, has approved the audited financial results (Standalone and Consolidated) along with Audit Report and Statement on Impact ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cian Healthcare Limited reported audited financial results for FY2026. The company came out of Corporate Insolvency Resolution Process (CIRP) with its Resolution Plan approved by NCLT on December 18, 2025, and became a subsidiary of Ananta Medicare Limited (55% holding). The auditors issued a Qualified Opinion citing multiple issues including inability to confirm trade receivables, advances and deposits; failure to obtain physical verification of PPE and CWIP; inventory revalued downward by INR 1,353.73 lakhs (from INR 1,956.90 lakhs to INR 603.10 lakhs); GST write-off of INR 347.28 lakhs without proper documentation; and absence of Internal Financial Controls documentation. Total comprehensive income stood at INR 1,499.51 lakhs including Other Comprehensive Income of INR 260.81 lakhs. Exceptional items totaling approximately INR 6,100 lakhs were recorded including inventory revaluation loss, write-offs of CWIP, deferred revenue, trade receivables, GST, and subsidiary investment provision/write-off. The wholly-owned subsidiary Dr. Smith's Biotech Private Limited is also under CIRP with operations halted since August 2024.
The qualified auditor opinion with multiple unresolved audit issues and the company's emergence from insolvency proceedings signals high risk. Shareholders should note the massive exceptional write-offs and inability of auditors to verify key balance sheet items, which creates significant uncertainty about the reliability of financial statements.